Ophthalmic cyclosporine use in ocular GVHD.
OBJECTIVE
To evaluate the safety and efficacy of topical ophthalmic cyclosporine in patients with dry eyes secondary to graft-versus-host disease (GVHD).


METHODS
Records of consecutive patients with ocular GVHD treated with topical cyclosporine were reviewed.


RESULTS
Thirty-two eyes of 16 patients were included with a mean follow-up of 90 days. Dry eye symptoms improved in 10 patients (62.5%), and corneal fluorescein staining improved in all eyes (P = 0.0039). Global physician impression was favorable in 12 patients (75%). Ocular burning or irritation was noted in 3 patients (19%), which improved with either continuation of cyclosporine at the current dosing regimen or reduction in dose and/or concentration of cyclosporine.


CONCLUSIONS
Ophthalmic cyclosporine seems to be safe and may be beneficial for patients with ocular GVHD, particularly those with more severe dry eyes.
Lelli
Gary J
GJ
Department of Ophthalmology and Visual Sciences, WK Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, MI 48105, USA.
Musch
David C
DC
Gupta
Anurag
A
Farjo
Qais A
QA
Nairus
Theresa M
TM
Mian
Shahzad I
SI
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000627:therapeutic use*; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D019793:Fluorescein; D005456:Fluorescent Dyes; D015590:Fluorophotometry; D006086:Graft vs Host Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D012189:Retrospective Studies
D005456:Fluorescent Dyes; D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016572:Cyclosporine; D019793:Fluorescein